糖尿病与非酒精性脂肪性肝病*

doi:10.3969/j.issn.1672-5069.2022.03.003

Abstract

Nian Fulin, Lu Xiaolan. Non-alcoholic fatty liver disease and diabetes mellitus type 2[J]. Journal of Practical Hepatology, 2022, 25(3): 314-317.

[1] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志, 2007, 10(1): 1-3.
[2] Younossi Z M. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019, 70(3): 531-544.
[3] Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022, 183:109119.
[4] Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med, 2018, 283(4): 356-370.
[5] Xu J Y, Yang L B, Han Z Y, et al. Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase. Oncotarget, 2021, 12(14): 1398-1405.
[6] Younossi Z M, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.J Hepatol, 2019, 71(4): 793-801.
[7] 邵勇, 徐静远, 鲁晓岚, 等. 非酒精性脂肪性肝病增加2型糖尿病发病率:一项基于苏南某镇农村老年人群的队列研究.中华肝脏病杂志, 2021, 29(09): 867-872.
[8] Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People. Hepatology, 2018, 68(4): 1308-1318.
[9] Mantovani A, Rigolon R, Mingolla L, et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complications, 2017, 31(6): 1021-1026.
[10] Mangla N, Ajmera V H, Caussy C, et al. Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol, 2020, 18(3): 744-746.
[11] Kitagawa N, Hashimoto Y, Hamaguchi M, et al. Liver Stiffness Is Associated With Progression of Albuminuria in Adults With Type 2 Diabetes: Nonalcoholic Fatty Disease Cohort Study. Can J Diabetes, 2020, 44(5): 428-433.
[12] Wan Y, Garner J, Wu N, et al. Role of stem cells during diabetic liver injury. J Cell Mol Med, 2016, 20(2): 195-203.
[13] 张永超, 李威. 糖尿病和非酒精性脂肪性肝病相关肝细胞癌的相互关系.临床肝胆病杂志, 2020, 36(10): 2329-2332.
[14] Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest, 2005, 115(5): 1139-1142.
[15] Roden M, Shulman G I. The integrative biology of type 2 diabetes. Nature, 2019, 576(7785): 51-60.
[16] Tilg H, Adolph T E, Moschen A R. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology, 2021, 73(2): 833-842.
[17] Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003, 361(9353): 226-228.
[18] Kim K, Kang J K, Jung Y H, et al. Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nat Commun, 2021, 12(1): 1822.
[19] Hedjazifar S, Khatib Shahidi R, Hammarstedt A, et al. The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH. Diabetes, 2020, 69(3): 331-341.
[20] Wu X, Shu L, Zhang Z, et al. Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells. Adv Sci (Weinh), 2021, 8(11): e2003721.
[21] Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep, 2019, 1(4): 312-328.
[22] 李川, 李莉. 2型糖尿病合并非酒精性脂肪性肝病的研究及治疗进展.中国继续医学教育, 2019, 11(04): 114-116.
[23] Yung J H M, Giacca A. Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells, 2020, 9(3): 706
[24] Solinas G, Becattini B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol Metab, 2016, 6(2): 174-184.
[25] Roshanzamir F, Miraghajani M, Rouhani M H, et al. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest, 2018, 41(1): 33-47.
[26] Tucker B, Li H, Long X, et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism, 2019, 101:153994.
[27] 任士萌, 梅璐, 黄煌, 等.非酒精性脂肪性肝病患者肠道菌群及生物化学指标相关性分析.中华肝脏病杂志, 2019, 27(05): 369-375.
[28] Alexander M, Loomis A K, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med, 2019, 17(1): 95.
[29] Kanwal F, Kramer J R, Li L, et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71(3): 808-819.
[30] Simon T G, King L Y, Chong D Q, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies.Hepatology, 2018, 67(5): 1797-1806.
[31] Berrou J, Fougeray S, Venot M, et al. Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One, 2013, 8(4): e62418.
[32] Wolf M J, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8⁺T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell, 2014, 26(4): 549-564.
[33] Ma C, Kesarwala A H, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531(7593):253-257.
[34] Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne), 2014, 5:10.
[35] Schwabe R F, Greten T F. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol, 2020, 72(2):230-238.
[36] Matson V, Chervin C S, Gajewski T F. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology, 2021, 160(2): 600-613.
[37] 刘志平, 赵致维, 张金华. 非酒精性脂肪性肝病患者肠道菌群与胰高血糖素样肽1的相关性分析. 临床肝胆病杂志, 2020, 36(01): 136-139.
[38] Hogan A E, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia, 2014, 57(4): 781-784.
[39] Lee Y S, Park M S, Choung J S, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia, 2012, 55(9): 2456-2468.
[40] Fang Q H, Shen Q L, Li J J, et al. Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. Hepatol Res, 2019, 49(7): 743-757.
[41] Kasumov T, Li L, Li M, et al. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One, 2015, 10(5): e0126910.
[42] Xu X, Shi X, Chen Y, et al. HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter. Metabolism, 2018, 85:126-138.

Non-alcoholic fatty liver disease and diabetes mellitus type 2

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Shisong, Lin Huixiong, Zhang Taisheng, et al. Short-term observation of metformin and dapagliflozin combination therapy in the treatment of patients with T2DM and NAFLD and their impact on serum dipeptidyl peptidase 4 and C-peptide levels [J]. Journal of Practical Hepatology, 2022, 25(3): 379-382.
[2]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[3]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[4]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.
[5]	Lyu Chunhui, Li Dawei, Wang Xiaojie, et al. Short-term impact of metformin an simvastatin combination therapy on blood glucose and lipid parameters in patients with nonalcoholic fatty liver disease with concomitant diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(1): 50-53.
[6]	Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.
[7]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.
[8]	Hao Xiaowei, Bai Na, Guo Xiaojun, et al. Correlationof serum adipocyte type fatty acid binding protein levels to glucose-lipid metabolism in patients with chronic hepatitis C and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 347-350.
[9]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.
[10]	SUN Lina, Gu Jing. Serum ferritin levels in patients withnon-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(2): 294-296.
[11]	Xia Shujing, Zhang Lili, Zhang Xiumei, et al. Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 43-46.
[12]	Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD [J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.
[13]	Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.
[14]	Liu Jian, Zhu Fengfa, Tang Juan. Ultrasonographic and biochemical features of patients with non-alcoholic heterogeneous fatty liver [J]. Journal of Practical Hepatology, 2020, 23(1): 42-45.
[15]	Wei Zhongcao, Liu Na, Xing Xin, et al. Efficacy and safety ofpolyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease: a Meta-analysis [J]. Journal of Practical Hepatology, 2020, 23(1): 46-49.